[Experimental and clinical studies on calcium lithiasis. II. Prevention of recurrent calcium stones with thiazides and allopurinol].
We evaluated 113 patients with recurrent or multiple calcium urolithiasis at our outpatient stone clinic between 1980 and 1983. Diagnostic categories included hypercalciuria (36 patients), hyperoxaluria (35 patients), and hyperuricosuria (31 patients). Thiazides and/or allopurinol were administered to the hypercalciurics and hyperuricosurics, respectively for prevention of stone recurrence. Patients followed up for more than one year were 23 (male 16, female 7) in the thiazide group, and 15 (male 12, female 3) in the allopurinol group. The mean treatment interval was 2.49 years in the former, and 2.35 years in the latter. The remission rate (percentage of patients without formation of any new stones) was 82.6% in the thiazide group, and 73.3% in the allopurinol group. The group stone formation rate was reduced from 0.85 to 0.35/pt-yr in the thiazide group, and from 0.74 to 0.27/pt-yr in the allopurinol group. Efficacy of these two drugs for the prevention of calcium stone recurrence was observed in this selective therapy, but a careful double blind study should be carried out to draw a definite conclusion.
D000493:Allopurinol / Q000627:therapeutic use*; D001581:Benzothiadiazines; D002118:Calcium / Q000032:analysis* / Q000652:urine; D004232:Diuretics; D005260:Female; D006801:Humans; D008274:Magnesium / Q000652:urine; D008297:Male; D010070:Oxalates / Q000652:urine; D019815:Oxalic Acid; D010710:Phosphates / Q000652:urine; D012008:Recurrence; D049993:Sodium Chloride Symporter Inhibitors / Q000627:therapeutic use*; D014545:Urinary Calculi / Q000209:etiology / Q000378:metabolism / Q000517:prevention & control*
D001581:Benzothiadiazines; D004232:Diuretics; D010070:Oxalates; D010710:Phosphates; D049993:Sodium Chloride Symporter Inhibitors; D000493:Allopurinol; D019815:Oxalic Acid; D008274:Magnesium; D002118:Calcium